Navigation Links
Genelabs Technologies Announces Presentation of Data on,Non-Nucleoside HCV Polymerase Inhibitor at 20th International,Conference on Antiviral Research Meeting

REDWOOD CITY, Calif., May 02, 2007 /PRNewswire-FirstCall/ -- Genelabs Technologies, Inc. announced today that a presentation was made today at the 20th International Conference on Antiviral Research being held in Palm Springs, California, on a non-nucleoside hepatitis C virus (HCV) polymerase inhibitor discovered by Genelabs.

The oral presentation was given by Christopher D. Roberts, Ph.D., Director of Medicinal Chemistry at Genelabs, entitled "GL59728: A Potent Allosteric Inhibitor of the HCV NS5b RNA Dependent RNA Polymerase with Excellent Pharmacokinetic Properties."

GL59728 is one of a number of non-nucleoside HCV polymerase inhibitors discovered by Genelabs. In the presentation, Dr. Roberts outlined the lead optimization of certain non-nucleoside HCV polymerase inhibitors through an iterative process involving testing for potency in directly inhibiting HCV NS5b polymerase, inhibiting the replication of an HCV sub-genomic replicon, and pharmacokinetic properties.

The optimized lead that emerged from this chemistry approach, one of several taken by Genelabs, is known as GL59728. The IC50 of GL59728 for inhibition of the HCV NS5b polymerase is 16 nanomolar and the EC50 for inhibition of HCV replicon is 170 nanomolar. Further, GL59728 shows excellent oral bioavailability, exceeding 50% in all four species tested, including higher-order species, low clearance and a half-life consistent with once- or twice-daily dosing. The tissue distribution of GL59728 also appears favorable; since its concentration is enhanced several fold in liver, the site of HCV infection, relative to that obtained in plasma. Importantly, GL59728 was also tested in combination with other classes of HCV antiviral compounds, including a nucleoside chain terminator, a protease inhibitor and interferon alpha, and shown to be additive in activity with each.

In June 2006 Genelabs entered into a license and research co
'"/>




Page: 1 2 3

Related medicine technology :

1. Neose Technologies to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. New Report Looking at Chiral Technologies Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
3. Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide
4. Palatin Technologies and King Pharmaceuticals Announce Plan To Present Results of Bremelanotide Phase 2b Studies in Men With Erectile Dysfunction
5. Micell Technologies Presents Data on Novel Drug-Eluting Stents
6. OncoGenex Technologies Announces Phase II Data of OGX-011 in Metastatic Breast Cancer at American Association for Cancer Research 2007 Annual Meeting
7. AVAX Technologies Presents Results of Phase I-II M-Vax Trial at Annual Meeting of American Association for Cancer Research
8. Emisphere Technologies, Inc. Reports Clinical Data on Oral Delivery of GLP-1 and PYY
9. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
10. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
11. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis

Post Your Comments:
(Date:11/25/2009)...rstCall/--Pharmasset,Inc.(Nasdaq: VRUS ),aclinical...evelopingandcommercializingnoveldrugstotreatvirali...endedSeptember30,2009.AtSeptember30,2009Pharmasset...investments. ,, PipelineUpdateand2009Highlight...ateNovember2009,anindependentDataMonitoringCommitt...
(Date:11/25/2009)...PRNewswire/-- FromNovember16-18,Phonak,theleadingm...hesecondeditionoftheHearingCareforAdultsConference...conferencebroughttogetherleadingexpertsinaginganda...whoworkeverydaywitholderpeoplewithhearinglossforan...searchandtrendsinhearingcareforolderpeople. ,,...
(Date:11/25/2009)...--TheFDAgrantedtraditionalapprovalforINTELENCE...riptaseinhibitor(NNRTI).INTELENCEistheonlyNNRTIspe...ltswhoareexperiencingvirologicfailurewithHIV-1stra...ents.Thetraditionalapprovalisbasedon48-weekdatafro...scurrentlymarketedintheU.S.byTibotecTherapeutics,a...
Breaking Medicine Technology:Pharmasset Reports Fiscal Year End 2009 Financial Results 2Pharmasset Reports Fiscal Year End 2009 Financial Results 3Pharmasset Reports Fiscal Year End 2009 Financial Results 4Pharmasset Reports Fiscal Year End 2009 Financial Results 5Pharmasset Reports Fiscal Year End 2009 Financial Results 6Pharmasset Reports Fiscal Year End 2009 Financial Results 7Pharmasset Reports Fiscal Year End 2009 Financial Results 8Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 2Phonak Successfully Hosts Hearing Care for Adults 2009 Conference 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 2U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 3U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine) 4Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection 28CDI 29 5005 1Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection 28CDI 29 5005 2Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection 28CDI 29 5005 3Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection 28CDI 29 5005 4Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection 28CDI 29 5005 5Optimer Announces Presentation of Additional Data From Fidaxomicin Phase 3 Study for the Treatment of Clostridium Difficile Infection 28CDI 29 5005 6The Celebrate Wellness Expo Presents Motivational Speaker 26 Author Dr Robin L Smith and Spiritual Teacher 26 Author Rev Michael Bernard Beckwith 57249 1The Celebrate Wellness Expo Presents Motivational Speaker 26 Author Dr Robin L Smith and Spiritual Teacher 26 Author Rev Michael Bernard Beckwith 57249 2ATS Medical to Participate at the 2009 UBS Global Life Sciences Conference 57246 1ATS Medical to Participate at the 2009 UBS Global Life Sciences Conference 57246 2
... Therapeutics, Inc. (Nasdaq: TPTX ) today announ...ial evaluating three doses of NGX267 as a treatmen...jogren,s syndrome. NGX267 met the primary endpoin...ary flow production compared to placebo at all thr...e safe and well tolerated with few reports of exce...
... (Nasdaq: MITI ), a biopharmaceutical company de...atment of cancer, inflammation and autoimmune dise...agreement expanding its Committed Equity Financing... a private investment group. Under the terms of t... up to $75 million of capital during the next thre...
Other Medicine Technology:TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 2TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 3TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 4TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 5Micromet Expands Committed Equity Financing Facility to $75 Million 2Micromet Expands Committed Equity Financing Facility to $75 Million 3Micromet Expands Committed Equity Financing Facility to $75 Million 4Micromet Expands Committed Equity Financing Facility to $75 Million 5Micromet Expands Committed Equity Financing Facility to $75 Million 6
(Date:11/25/2009)...BroadPoliticalEndorsements,Business,andPressJoinEf...re-USNewswire/--Onceagain,theNationalBipolarFounda...endorsingtheir"Safe,tilStable"program,whichisnowbe...bipolardisorder.Today,theNationalBipolarFoundation...sPriorityMailfromtheLt.GovernorofLouisianaMitchLan...
(Date:11/25/2009)...tuitous discovery that grew out of a collaboration...tially offer hope to the nearly 10 million America... , Also known as hardening of the arteries, per...ulatory problem in which narrowed arteries reduce ...ed a red flag for vascular disease, heart attack a...
(Date:11/25/2009)..., already used to fight rheumatoid arthritis, coul... , WEDNESDAY, Nov. 25 (HealthDay News) -- A...a and rheumatoid arthritis now also shows some pro... 1 diabetes. , The drug, rituximab (Rituxan), h...sulin, even though the disease had destroyed some ...
(Date:11/25/2009)... often plagued by neurological symptoms, study fin...ws) -- Neurological side effects are among the pot...sticular cancer who were treated with cisplatin-ba...study included 1,409 Norwegian men treated for uni...o took part in a follow-up survey conducted from 1...
(Date:11/25/2009)...RLINGTON,Va.,Nov.25/PRNewswire-USNewswire/--TheAme...ealthCareFraudActof2009,"S.2128,whichisdesignedtos...ventfraudinMedicare.ThebillwasintroducedbySen.Geor...eralprovisionstheAmericanAssociationforHomecareout...ociationproposedtoCongressinFebruary.Thoseprovisio...
Breaking Medicine News(10 mins):Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 2Health News:First Time-Door is Open for Family Discussion of Bipolar Disorder 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 2Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 3Health News:Engineers, doctors at UCLA develop novel material that could help fight arterial disease 4Health News:Type 1 Diabetes May Have a New Foe 2Health News:Type 1 Diabetes May Have a New Foe 3Health News:American Association for Homecare Endorses New U.S. Senate Bill, the 'Prevent Health Care Fraud Act of 2009' 2
...itute for Biological Studies during embryonic deve...produce// tentacle-like protrusions. These are cal...r destination. They guide the nerve cells through ...in the limb, scientists at the Salk Institute for ...
...s on obesity finalized to cause harm to children, .... Due to financial agreements made between t...ing this proposal, an unfit guideline was being ma...rican Medical Association has ‘tentatively decided...
...n makes women more disabled than men – study publi...s treatment procedures targeting to reduce stress ...reduce disability. This suggests that by targe... which involved 260 chronic pain patients from Roy...
...act fast when their reputation is at stake. Now th...nd credibility by doing something solid about all ...hicken, Wendy's, McDonald's and Burger King are al...nt. Jeff O'Neill, president and chief operat...
...omen, women overweight in their teens or later are...r. // This research was conducted by scientists at...The participants of the study were some 2,110 wome... were more likely to develop the disease compared ...
... portion of the horses in the Meath/Kildare region...g to reports from The Department of Agriculture an...ne Infectious Anemia, has an incubation period of ...s are being conducted to ascertain the facts. Ther...
Other Medicine News:Health News:Growth Factors Help Neurons to Reach Their Correct Destination 2Health News:Growth Factors Help Neurons to Reach Their Correct Destination 3Health News:New Obesity Guidelines Will Trouble US Children 2Health News:Depression And Chronic Pain Cause Disability In Women 2
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
...ratories is a national reference laboratory and a ... and development. ARUP offers an extensive test me...linical and anatomic pathology. Owned by the Unive...more than half of the nation's university teaching...
Medicine Products: